Amgen Proudly Supports PhRMAs New Principles on Clinical Trial Diversity | Amgen

Amgen Proudly Supports PhRMA’s New Principles on Clinical Trial Diversity

November 17, 2020

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) announced first-ever, industry-wide principles on clinical trial diversity. The principles focus on four main areas: building trust and acknowledging the historic mistrust of clinical trials within Black and Brown communities, reducing barriers to clinical trial access, using real-world data to enhance information on diverse populations beyond product approval and enhancing information about diversity and inclusion in clinical trial participation.

Learn more about our commitment to increasing patient diversity here:

PhRMA Announces First-Ever, Industry-Wide Principles on Clinical Trial Diversity